124 related articles for article (PubMed ID: 4053265)
1. Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.
Pendyala L; Madajewicz S; Lele SB; Arbuck SG; Creaven PJ
Cancer Chemother Pharmacol; 1985; 15(3):203-7. PubMed ID: 4053265
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity.
Goren MP; Forastiere AA; Wright RK; Horowitz ME; Dodge RK; Kamen BA; Viar MJ; Pratt CB
Cancer Chemother Pharmacol; 1987; 19(1):57-60. PubMed ID: 2880677
[TBL] [Abstract][Full Text] [Related]
3. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation.
Kawai Y; Taniuchi S; Okahara S; Nakamura M; Gemba M
Biol Pharm Bull; 2005 Aug; 28(8):1385-8. PubMed ID: 16079479
[TBL] [Abstract][Full Text] [Related]
4. [Antineoplastic therapy and urinary enzymes. Preliminary note on the determination of urinary N-acetyl-beta-D-glucosaminidase in patients treated with cisplatin].
Crovato E; Salvini R
Boll Soc Ital Biol Sper; 1984 Dec; 60(12):2255-60. PubMed ID: 6543318
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
6. Urinary excretion of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase in patients receiving amikacin or cis-platinum.
Diener U; Knoll E; Langer B; Rautenstrauch H; Ratge D; Wisser H
Clin Chim Acta; 1981 May; 112(2):149-57. PubMed ID: 6113066
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of urinary enzyme measurements in hypertension.
Johnston ID; Jones NF; Scoble JE; Yuen CT; Price RG
Clin Chim Acta; 1983 Oct; 133(3):317-25. PubMed ID: 6414744
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of urinary enzymes in diabetes mellitus].
Morita E; Kaizu K; Uriu K; Eto S
J UOEH; 1990 Jun; 12(2):197-205. PubMed ID: 1975116
[TBL] [Abstract][Full Text] [Related]
9. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9).
Skillen AW; Buamah PK; Cantwell BM; Cornell C; Hodson AW; Harris AL
Cancer Chemother Pharmacol; 1988; 22(3):228-34. PubMed ID: 3044631
[TBL] [Abstract][Full Text] [Related]
10. [Urinary enzyme excretion in nephropathia--with special reference to chance proteinuria and/or hematuria].
Okura T; Tawada H; Matsuo S; Sato Y; Miyauchi J; Ando I; Oshida Y; Ishiguro T; Sakamoto N
Nihon Jinzo Gakkai Shi; 1984 Jun; 26(6):791-803. PubMed ID: 6151009
[No Abstract] [Full Text] [Related]
11. Phase I study of weekly-administered iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropylamine platin (chip, JM9)].
Chawla SP; Yap BS; Tenney DM; Bodey GP; Benjamin RS
Invest New Drugs; 1988 Dec; 6(4):311-7. PubMed ID: 3229943
[TBL] [Abstract][Full Text] [Related]
12. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
13. Urine and serum leucine aminopeptidase, N-acetyl-beta-glucosaminidase and gamma-glutamyl transpeptidase activities in diabetics with and without nephropathy.
Cohen N; Gertler A; Atar H; Bar-Khayim Y
Isr J Med Sci; 1981 Jun; 17(6):422-5. PubMed ID: 6114940
[TBL] [Abstract][Full Text] [Related]
14. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
15. Lysosomal and brush border membrane enzymes in urine of patients with renal artery stenosis and with essential hypertension.
Maruhn D; Paar D; Bock KD
Clin Biochem; 1979 Dec; 12(6):228-20. PubMed ID: 43780
[No Abstract] [Full Text] [Related]
16. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230
[TBL] [Abstract][Full Text] [Related]
17. Lung tumour growth delay and normal tissue toxicity induced by three cytotoxic platinum drugs.
van Rongen E; Kal HB; Kuijpers WC; van Berkel AH
Strahlenther Onkol; 1992 May; 168(5):300-7. PubMed ID: 1598667
[TBL] [Abstract][Full Text] [Related]
18. Clinical development of iproplatin (CHIP).
Creaven PJ; Pendyala L; Madajewicz S
Drugs Exp Clin Res; 1986; 12(1-3):287-92. PubMed ID: 3732051
[TBL] [Abstract][Full Text] [Related]
19. The excretion of urinary N-acetyl-beta-glucosaminidase and beta-glucuronidase as a sign of impending rejection of kidney transplants.
Koivula T; Pitkänen E; Turto H; Tötterman T
Ann Clin Res; 1978 Oct; 10(5):288-90. PubMed ID: 367256
[TBL] [Abstract][Full Text] [Related]
20. Ultrafiltration for improved assay of urinary enzymes.
Werner M; Gabrielson D
Clin Chem; 1977; 23(4):700-4. PubMed ID: 844164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
